Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence— results of a prospective multi-centre study
- 1 August 2021
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 47 (8) , 2150-2157
Abstract
No abstract availableKeywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish studyGynecologic Oncology, 2014
- Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?Gynecologic Oncology, 2013
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)International Journal of Gynecological Cancer, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Residual Cancer Stem Cells after Interval Cytoreductive Surgery following Neoadjuvant Chemotherapy Could Result in Poor Treatment Outcomes for Ovarian CancerOnkologie, 2010
- “Stemness” Genomics Law Governs Clinical Behavior of Human Cancer: Implications for Decision Making in Disease ManagementJournal of Clinical Oncology, 2008
- Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis1996
- The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian CancerNew England Journal of Medicine, 1995